InSynchrony Ventures is a new breed of biotech investor that strongly believes in the concept of "smart money". We’ve combined InSynchrony’s capital with the proven expertise of InSymbiosis (a collaborative drug development company that was previously established by one of the founders of InSynchrony) to deliver a unique investment formulation. Furthermore, we focus on the earlier phases of development where most of the funding challenges exist. We believe that providing the capital and expertise at this crucial moment is key to allowing new inventions and technologies to show their true potential.
Dean has over 20 years of combined drug development and business experience. After completing a Ph.D. in Pharmacology at University College London he worked as a drug developer at both large pharmaceutical companies (Pfizer and AstraZeneca) and at small biotechs. Dean leveraged this valuable pharma industry experience to launch InSymbiosis in 2005 as a platform to improve the costs, timelines, and overall efficiency of the drug development process largely focused on small biotechs. InSynchrony Ventures is an extension of Dean’s vision of enabling early drugs to show their promise. At InSynchrony, he leads the investment scouting process, participates in due diligence, and conducts the deal closing process. Dean also serves as a board member for several of the portfolio companies.
Rudi studied the interaction of lipids with proteins in Biophysics at Berlin’s Humboldt University. After moving to Montreal, he obtained his Ph.D. at McGill University, in conjunction with Humboldt University. He investigated the regulation of eicosanoid synthesis by oxidative stress. Rudi then became a DMPK scientist at Charles River Laboratories in Montreal and extended his experience into full-blown drug development before joining InSymbiosis as a senior scientist. At InSynchrony, Rudi participates in the scouting process and leads many of the due diligence efforts.
Armed with a Ph.D. in Molecular Biology from the University of Laval, Alain started his pharma career with Topigen, an emerging Montreal based biotech company developing novel antisense oligo therapeutics for respiratory diseases. At Topigen he gained valuable experience in discovery, CMC-Manufacturing, GLP toxicology and early phase clinical studies, as well as regulatory interactions. This expertise grounded Alain well for leading the drug development team at InSymbiosis. At InSynchrony, Alain partakes in the due diligence process and provides core scientific and drug development support to the investee companies.
InSynchrony Ventures’ interests and expertise lie in early stage therapeutics development. Therefore, from an investment perspective, we are most interested in therapeutic companies whose programs are between preclinical and early clinical stages. We are therapeutically agnostic and typically require that the company has the following profile:
To begin the discussion, please submit a non-confidential presentation and/or executive summary for review.
Colorado-based Cetya Therapeutics (“Cetya”) is part of InSynchrony Ventures’ investment portfolio and we are excited to share that…
We announced our participation in the seed financing of Atriva Therapeutics back in July and are delighted to…
Following the creation of InSynchrony Ventures in 2016 and the announcement of our new strategic investment vehicle in…
Copyright © 2017 InSynchrony Ventures. All rights reserved. Creation by Netfolie.com